4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Vitiligo by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 96 ongoing clinical trials involving Vitiligo
Of the 96 trials,45 trials are in Phase II
Furthermore, 19 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Vitiligo by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Vitiligo, a Dermatology condition. The largest number of ongoing clinical trials for Vitiligo is conducted in the Asia-Pacific region. North America and Middle East and Africa are among some of the other prominent regions engaged in Vitiligo-related drug trials.

Pfizer Inc: The leading ongoing Vitiligo related clinical trial sponsor

Pfizer Inc is the top sponsor for Vitiligo-related ongoing clinical trials.

Incyte Corp, Postgraduate Institute of Medical Education and Research, Cairo University and Ain Shams University are among other notable clinical trial sponsors involved in Vitiligo. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Vitiligo

Aminobenzoic acid and methoxsalen (Melanocyl), Bifonazole (Mycospor, Canesten, Mycospor Onychoset, Meike, Canesten Unidie, Canesderm Pie, Canestene Derm, Canespie, Canesten Bifonazole, Canesten Pro) and Carpronium chloride (Arovics) are among the key marketed drugs involving Vitiligo.

Aminobenzoic acid and methoxsalen (Melanocyl) is fixed dose combination acts as an anti-vitiligo agent. It functions via 5- DNA Synthesis Inhibitor mechanism of action. Aminobenzoic acid is formulated as ointment for topical application. It is indicated for the treatment of psoriasis and vitiligo. Aminobenzoic acid is marketed solely in India by Franco-Indian Pharmaceuticals Pvt Ltd.

Bifonazole is an azole antifungal drug. It functions via Lanosterol 14 Alpha Demethylase Inhibitor mechanism of action. Bifonazole is formulated as cream, ointment, gel, spray, powder, shampoo and solution for topical application. Bifonazole was first approved in 1982 and is marketed globally in Australia, UK, China, Japan, Russia and Germany by several prominent pharma giants including Bayer Australia Ltd.